TAADIM LDLT , Trial comparing Tacrolimus based immunosupression in living donor liver transplantatio
Phase 4
- Conditions
- Health Condition 1: K746- Other and unspecified cirrhosis ofliver
- Registration Number
- CTRI/2019/01/016913
- Lead Sponsor
- Amrita Institute of medical sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.All patients above 18 years
2.Patients who are recipient of primary liver allografts from a living donor.
3. Patients who are capable of understanding and giving written informed consent to be a part of the study.
Exclusion Criteria
1. Deceased donor liver transplant recepients
2. Multiorgan transplants
3. ABO incompatible grafts
4. Recent chemotherapy before transplantation
5. Intolerance to study medications
6. Pediatric transplant
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.The primary endpoint is eGFR estimated by CKD-EPI and cystatin clearance at 1,3 and 6 monthsTimepoint: 1,3 and 6 months
- Secondary Outcome Measures
Name Time Method Biopsy proven acute cellular rejectionTimepoint: Within 6 months post transplant;New onset diabetes mellitus,New onset systemic hypertension and Hypercholesterolemia. <br/ ><br>Timepoint: Within 6 months post transplant;Post transplant graft function , Patient survival and graft survival, Post transplant infectious complications, Post transplant hospital stay, Post transplant biliary or vascular complications, Incidence of tremor and neurotoxicityTimepoint: Within 6 months post transplant;Serum tacrolimus levels attainedTimepoint: Measured twice weekly in first month, then once in two weeks for next two months and then monthly